Key Takeaways
- Volume-led Q4 recovery, but YoY still deep in the red: Revenue rose 6.3% QoQ on >11% volume growth, yet remains down 25% YoY, showing the climb back is steep.
- Isostearic acid is the growth story that is finally becoming real: Commercial orders have begun, ~16 customer approvals are in hand, and management expects a ramp through H1 FY26 with optimum utilization by next year.
- A new product cycle is being built, but it will take time: One-third of installed capacity is already earmarked, equipment is ordered, and trials are slated for January-March, though commercial approvals will be long because Fairchem would be India's first producer.
- Margins are under raw material pressure with no quick fix: Higher raw material costs compressed EBITDA, and a September 2024 import duty on dimer acid feedstock is an overhang management cannot resolve alone, calling itself "the only player in India."
- What to watch next quarter: Whether the Isostearic acid commercial ramp actually accelerates in H1 as promised, any movement on the dimer acid duty, and whether paint sector demand revives in the October-December window.
Isostearic Acid: The Commercial Breakthrough
- From trials to orders: Quite a few commercial orders have started going, moving beyond the trial phase that characterized earlier quarters.
- Customer base building: ~16 approvals received so far, with entry barriers high because of long qualification cycles, but once a customer is locked in, exit is equally tough.
- Global supply shortage works in Fairchem's favor: Only 4 players worldwide, Fairchem is the 5th, and demand outstrips supply because the product is biodegradable and sought after in developed markets.
- Ramp trajectory: Volumes will pick up in the first half of the current financial year versus the prior six months, with a further step-up in the second half; optimum utilization expected by next year (FY26).
- Product quality claim: Management asserts quality is on par with world players, and the market is welcoming a new entrant.
Nahoosh Jariwala: "And only thing is that there are just 4 players in the world. So everyone is excited to have a new player like us. And so we are getting a positive..."
New Product Pipeline
- Capacity already reserved: Out of 120,000 MT installed capacity, 40,000 tons, one-third, is earmarked for the new product.
- Equipment timeline: All specialty equipment ordered, taking approximately 6 months to arrive; management expects to have everything before end of December, with trials in the January-March period.
- First-mover burden: Fairchem will be the first producer in India; globally only 2 players in Europe and 1-2 in China, so commercial approval cycles will be long.
- No revenue timeline given: Management did not commit to when commercial production or revenue would begin, only that trials start in early 2026.
Demand Environment
- Paint sector holding up, not thriving: Sales to top paint industry players remain fairly comfortable because Fairchem's product is one-of-a-kind, with only minor downside in demand, though the monsoon quarter typically sees lower paint activity.
- Recovery bet is on Q3: Management expects paint sector demand to revive in the October-December quarter.
- Industry tailwind intact: Forecasted industry CAGR of over 12%, driven by growing demand in cosmetics, home care, and industrial additives.
- Peak demand question dodged: When asked when paint industry demand could return to 2022 peak levels, management said it is "very difficult to predict what will happen in the next 2-3 years."
Margin & Cost Pressures
- Raw material costs the culprit: EBITDA margin declined primarily due to relatively higher raw material costs.
- Dimer acid duty overhang: The government imposed a duty in September 2024 that increased the price of raw material used for dimer acid, limiting Fairchem's ability to absorb pressure on higher dimer sales unless the duty is reversed.
- Sole-manufacturer disadvantage: Being the only Indian producer makes it tough to get government attention on the duty issue; management cannot say when it might be resolved.
- Isostearic acid margin profile undisclosed: Management declined to say whether the product is at breakeven or positive EBITDA, calling it a "business secret" and citing the interest of 30,000 shareholders.
Nahoosh Jariwala: "Being the only player in India, it is really tough. We are trying our best, but I cannot say when it will happen."
Rajen Jhaveri: "See, when government imposed this particular duty, they would have seen a larger interest of farmer community prima facie as it appears. So, it is highly unlikely that our sole request may receive substantial attention from the government."
Capacity Utilization & Volume Recovery
- Near-term confidence: Management is confident of achieving higher capacity utilization by the end of this year (2025).
- Q4 volume jump: Volume increased over 11% QoQ, driving the 6.3% sequential revenue gain, though the 25% YoY revenue decline shows how much ground was lost.
- Isostearic acid as the utilization driver: The ramp-up of Isostearic acid volumes through FY26 is the primary lever to fill capacity, with optimum utilization targeted by next year.
Industry & Competitive Context
- Challenging macro for Indian specialty chemicals: The sector faces domestic cost pressures, global volatility, geopolitical shifts, potential US tariffs on chemical imports, China Plus One supply chain realignment, and shifting economic alliances disrupting trade flows.
- Isostearic acid moat: Only 4 global players plus Fairchem; high entry barriers from long trials and approvals; once a supplier is qualified, switching costs are high.
- Biodegradable demand driver: The product's biodegradable profile is driving demand in developed countries, with supply currently short of demand.
- Cost competitiveness undisclosed: Management gave a general answer about raw material being monobasic acid and co-products having realizable value, but did not provide comparative cost data versus the other 4 global players.
Rajen Jhaveri: "This is all a part of a business secret. And in this concall, subsequently placed on the stock exchanges of BSE, NSE and then everybody has a look at it. In the interest of our 30,000 shareholders only, it will be better if we refrain from answering certain questions in the interest of our 30,000 shareholders."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Higher capacity utilization | Confident of achieving it | By end of 2025 |
| Isostearic acid volume ramp | Pick up vs prior 6 months, then further step-up | H1 FY26, then H2 FY26 |
| Isostearic acid optimum utilization | Reach optimum utilization | By next year (FY26) |
| New product equipment readiness | All equipment received | Before end of December 2025 |
| New product trials | Trials begin | January-March 2026 |
| Paint sector demand recovery | Demand revives | October-December 2025 quarter |
| Dimer acid duty reversal | Government may act | By FY26-27, when Isostearic acid optimizes |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from operations | ₹121 cr, +6.3% QoQ, -25% YoY |
| EBITDA | ~₹4 cr, margin at 3.64% |
| Net profit after tax | ~₹60 lakhs |
| Full-year FY25 revenue | ₹538 cr |
| Full-year FY25 EBITDA | ~₹43 cr, margin at 7.96% |
| Full-year FY25 net profit after tax | ~₹22 cr |
| Volume sold | ~5,500 tons, up from 4,674 tons in Q3 FY25 |
| Volume growth | >11% QoQ |
| Value growth | >6% QoQ |
| Installed capacity (raw material throughput) | 120,000 metric tons per annum |
| Capacity earmarked for new product family | 40,000 tons, one-third of installed capacity |
| Isostearic acid customer approvals received | ~16 |
| Isostearic acid optimum utilization expected | By FY27 |